Multiple myeloma (MM) is the second most common hematologic cancer, with an estimated worldwide incidence of over 175鈥�000 newly diagnosed patients annually and over 130鈥�000 patients living with the disease in the US.1 Although there is not yet an established curative therapy, the past couple of decades have been heralded by the development of novel therapeutics translating into patients with myeloma living longer. This is especially highlighted by the US Food and Drug Administration (FDA) approvals of the first monoclonal antibody鈥揵ased immunotherapies鈥攖he recent most exciting drugs have been those interrogating the immune system, either in vivo or ex vivo. Where historically patients derived only modest clinical benefit from traditional cytotoxic chemotherapies鈥攆raught with significant toxicity鈥攎odern novel immunotherapies have not only significantly improved efficacy but have increased tolerability and quality of life for patients in this new era of MM.